MutaGen™: We have developed and patented a new and innovative DME technology, for any protein based product improvement (antibodies for therapy and diagnostics, antigen for in vitro diagnostic application, therapeutic proteins, and industrial enzymes)
MutalBanks: Fully human monoclonal antibodywas genetically engineered with high diversity. In addition, a proofreading process has enriched the library with open reading frame (ORF) antibody sequences and improved the library quality selecting soluble antibodies. This new generation of library of 3.4 billion clones is the higher quality library on the market with 94 % of clones encoding full-length and functional antibodies. The high rate of functional antibodies allow a rapid and successful screening in order to provide an even wider range of promising antibody drug candidates per target.
MilleMab: Our new comprehensive platform includes cloning, humanisation, optimisation and Immunogenicity risk limitation, when starting from a rodent MAb.
CPPI: Cytoplasmic Protein Protein Interaction. Our yeast based screening system is dedicated to protein-protein interaction detection and drug discovery (peptides, intrabodies).
MilleGate : Integrated to our antibody discovery platform, MilleGate is a web-based toolbox suitable for any DME project which integrates specialized tools dedicated to antibody studies. This bioinformatics toolbox and database allow filtering, selecting, doing statistics and annotating a wide diversity of variants sequences generated by DME platform. MilleGate integrates a public and proprietary database in order to explore relevant functional relationship surrounding the antibody of interest and to provide information on what kinds of functional influences at a specific position on protein sequence by taking into account industrial property situation.
